Morgan Keegan Overweight on Edwards Lifesciences

Morgan Keegan is out with a research report on Edwards Lifesciences Corporation EW and it has an Overweight rating and a $91 price target on shares. In a note to clients, Morgan Keegan writes, "Investors are awaiting the approval of Edwards Sapien Valve, and we want to reiterate our conviction that the approval is imminent. Edwards is rated Outperform with a $91 Price Target." Shares of EW gained 60 cents on Friday to close at $76.06.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsMorgan Keegan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!